

Please try another search
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Monmouth Junction, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Jedd D. Wolchok | - | - | Member of Scientific Advisory Board |
Nancy Freitag | - | - | Member of Scientific Advisory Board |
Marc Lecuit | - | - | Member of Scientific Advisory Board |
Antoni Ribas | 54 | - | Member of Scientific Advisory Board |
Robert G. Petit | 61 | 2010 | Chairman of Scientific Advisory Board |
James P. Patton | 63 | 2002 | Independent Vice Chairman of the Board |
Roni A. Appel | 54 | 2004 | Independent Director |
David Sidransky | 61 | 2013 | Independent Chairman |
Samir N. Khleif | 57 | 2014 | Independent Director |
Richard Jay Berman | 78 | 2005 | Independent Director |
Kenneth A. Berlin | 58 | 2018 | President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review